Choi Kyoung-Hee, Mima Takehiko, Casart Yveth, Rholl Drew, Kumar Ayush, Beacham Ifor R, Schweizer Herbert P
Department of Microbiology, Immunology and Pathology, Rocky Mountain Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research, Colorado State University, Fort Collins, CO 80523-1682, USA.
Appl Environ Microbiol. 2008 Feb;74(4):1064-75. doi: 10.1128/AEM.02430-07. Epub 2007 Dec 21.
Because of Burkholderia pseudomallei's classification as a select agent in the United States, genetic manipulation of this bacterium is strictly regulated. Only a few antibiotic selection markers, including gentamicin, kanamycin, and zeocin, are currently approved for use with this bacterium, but wild-type strains are highly resistant to these antibiotics. To facilitate routine genetic manipulations of wild-type strains, several new tools were developed. A temperature-sensitive pRO1600 broad-host-range replicon was isolated and used to construct curable plasmids where the Flp and Cre recombinase genes are expressed from the rhamnose-regulated Escherichia coli P(BAD) promoter and kanamycin (nptI) and zeocin (ble) selection markers from the constitutive Burkholderia thailandensis ribosomal P(S12) or synthetic bacterial P(EM7) promoter. Flp and Cre site-specific recombination systems allow in vivo excision and recycling of nptII and ble selection markers contained on FRT or loxP cassettes. Finally, expression of Tn7 site-specific transposase from the constitutive P1 integron promoter allowed development of an efficient site-specific chromosomal integration system for B. pseudomallei. In conjunction with a natural transformation method, the utility of these new tools was demonstrated by isolating an unmarked delta(amrRAB-oprA) efflux pump mutant. Exploiting natural transformation, chromosomal DNA fragments carrying this mutation marked with zeocin resistance were transferred between the genomes of two different B. pseudomallei strains. Lastly, the deletion mutation was complemented by a chromosomally integrated mini-Tn7 element carrying the amrAB-oprA operon. The new tools allow routine select-agent-compliant genetic manipulations of B. pseudomallei and other Burkholderia species.
由于类鼻疽伯克霍尔德菌在美国被列为特定病原体,对该细菌的基因操作受到严格监管。目前仅批准了少数几种抗生素选择标记物用于该细菌,包括庆大霉素、卡那霉素和博来霉素,但野生型菌株对这些抗生素具有高度抗性。为便于对野生型菌株进行常规基因操作,开发了几种新工具。分离出一种温度敏感型pRO1600广宿主范围复制子,并用于构建可治愈质粒,其中Flp和Cre重组酶基因由鼠李糖调节的大肠杆菌P(BAD)启动子表达,卡那霉素(nptI)和博来霉素(ble)选择标记物由组成型泰国伯克霍尔德菌核糖体P(S12)或合成细菌P(EM7)启动子表达。Flp和Cre位点特异性重组系统允许在体内切除和循环利用FRT或loxP盒上包含的nptII和ble选择标记物。最后,来自组成型P1整合子启动子的Tn7位点特异性转座酶的表达使得能够开发一种用于类鼻疽伯克霍尔德菌的高效位点特异性染色体整合系统。结合自然转化方法,通过分离一个无标记的delta(amrRAB-oprA)外排泵突变体证明了这些新工具的实用性。利用自然转化,携带这种带有博来霉素抗性标记的突变的染色体DNA片段在两种不同的类鼻疽伯克霍尔德菌菌株的基因组之间转移。最后,通过携带amrAB-oprA操纵子的染色体整合微型Tn7元件对缺失突变进行了互补。这些新工具允许对类鼻疽伯克霍尔德菌和其他伯克霍尔德菌属物种进行符合特定病原体要求的常规基因操作。